ESMO 2021, News
There was no improvement in overall survival with bevacizumab.
ESMO 2021, News
Pembrolizumab plus chemotherapy with or without bevacizumab could be a new standard of care for first-line therapy in metastatic cervical cancer.
ESMO 2021, News
The checkpoint inhibitor cemiplimab improved survival in patients with recurrent/metastatic cervical carcinoma compared with single-agent chemotherapy.